Wednesday, May 9, 2012
Advaxis Inc., of Princeton, N.J., said two patients have been enrolled into a Phase I/II study sponsored by Cancer Research UK to test immunotherapy candidate ADXS-HPV for the treatment of human papillomavirus (HPV)-positive head and neck cancer.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.